Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Tuberculosis
Interventions: BCG strain Connaught, BCG strain Danish, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Subjects
Interventions: DZD9008 and intraconazole, DZD9008 and carbamazepine; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Adult Participants
Interventions: Functional Connectivity fMRI Neurofeedback, ROI-Activity fMRI Neurofeedback; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: PF-06372865, itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Healthy Subject
Interventions: Dietary Fiber, Fish Oil, Comparator; Dietary Supplement · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Talampanel (non-radiolabeled), [14C] Talampanel; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimer Disease
Interventions: MNI-513-01; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 55 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Healthy, Chronic Stable Illness
Interventions: Casirivimab+Imdevimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Winter Park, Florida

Conditions: Healthy
Interventions: PRT064445, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers
Interventions: Bimatoprost Ophthalmic; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: SKI-606; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer
Interventions: RO4917523, RO5011232; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Subjects
Interventions: Clemastine fumarate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lyme Disease
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 19
States / cities: Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more

Conditions: Healthy Volunteer
Interventions: danoprevir, omeprazole, ranitidine, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Dystonia
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: New Haven, Connecticut • Overland Park, Kansas

Conditions: Healthy Subjects, Purpura, Thrombocytopenic, Idiopathic
Interventions: eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity, Healthy Volunteers
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

A Phase 1 QT Study in Healthy Male Subjects

Neuroanatomically Informed fMRI Neurofeedback in Healthy Adults

Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Effect of Clemastine Fumarate on Color Vision in Healthy Controls

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

Eltrombopag Taste Testing in Healthy Adult Volunteers

Fat Metabolism and Melanocortin 3 Receptors in African Americans